COMPASSIONATE USE OF AN INTRAVENOUS FAT EMULSION COMPRISED OF FSIH OIL IN THE TR

在 TR 中善意地使用由 FSIH 油组成的静脉脂肪乳剂

基本信息

  • 批准号:
    8356700
  • 负责人:
  • 金额:
    $ 2.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-12-01 至 2011-11-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ABSTRACT We propose to provide an omega-6 predominant lipid infusion (Omegaven) to patients with severe parenteral nutrition associated cholestasis (conjugated bilirubin 6) on a compassionate use basis. We will monitor for safety parameters during the maximum 5 months of intervention. The Omegaven will be intravenously infused at a dose of 1gm/kg/day until the infant is weaned from parenteral nutrition and for no longer than 5 months. This is a continuation of protocol H-21344. I. HYPOTHESIS Not applicable due to the compassionate use nature of this protocol. II. SPECIFIC AIMS To provide a mechanism for critically ill infants with parenteral nutrition (PN) associated cholestasis to receive Omegaven for compassionate use situations for which there are no satisfactory alternative treatments. III. BACKGROUND AND SIGNIFICANCE Parenteral nutrition (PN) provides intravenous nutritional supplementation for patients unable to absorb adequate enteral nutrients secondary to insufficient intestinal length or function. PN contains the macronutrient building blocks of the human diet in their most elemental forms (amino acids and dextrose) and is commonly administered with a lipid emulsion to avoid essential fatty acid deficiency and to provide a calorically dense source of non-protein calories. In addition, PN contains the essential micronutrients (electrolytes, trace elements, and vitamins) to provide an optimal nutritional regimen. Before the development of PN in the late 1960s, patients with insufficient gastrointestinal absorptive function commonly died of starvation and subsequent complications of malnutrition (1, 2). Today, more than 30,000 patients are permanently dependent on parenteral nutrition for survival. However, PN continues to be associated with hepatic injury that occurs at an unpredictable rate and includes both biochemical, i.e., elevated serum aminotransferase and alkaline phosphatase, and histologic alterations such as steatosis, steatohepatitis, lipidosis, cholestasis, fibrosis, and cirrhosis (3, 4). These abnormalities, which may worsen with the duration of PN administration, is more prevalent in the pediatric population. Additional risk factors for this condition include prematurity, low birth weight, long-term use of PN, the lack of concomitant enteral intake, sepsis, and multiple operative procedures (5). Although the pathological features of PN-induced liver injury have been well described, the etiology, prevention, and treatment of this complication are not well understood. Multiple hypotheses exist to explain the pathogenesis of PN-induced liver injury including altered gut hormonal profiles (6), the propensity for bacterial translocation in the absence of enteral intake (7, 8), intestinal stasis resulting in the reduced clearance of hepatotoxic bile acids (8), and direct deficiencies or toxic components of the PN solution itself resulting in excessive glucose calorie uptake, excessive lipid infusion, or nutritional deficiencies such as essential fatty acid deficiency (9-11). None of these theories has been confirmed consistently. The etiology of PN-associated hepatotoxicity is currently considered multifactorial. Available treatment options for this disease process are limited and have achieved moderate success at best. Care of the PN-dependent patient is focused on gradually increasing enteral caloric intake as the residual bowel adapts allowing PN to be discontinued (12). In fact, it has been shown both experimentally and clinically that partial enteral nutrition, when tolerated, helps to protect against the development of PN-associated liver injury (13-15). In severe cases of refractory hepatic failure, liver transplantation with or without accompanying small bowel transplantation remains the only treatment option. The mechanism of clearance of omega-3 fatty acid containing lipid emulsions is unknown, but appears to be largely independent of the pathways identified above (17). Furthermore, omega-3 fatty acid solutions have been shown to decrease de novo lipogenesis (18), prevent or attenuate PN-induced hepatosteatosis in rats (19) and guinea pigs and ameliorate the severity of high-fat diet-induced hepatosteatosis in rats (20). In addition, omega-3 fatty acids can interfere with the arachidonic acid pathway of inflammation (18, 21). They can displace arachidonic acid from tissue fatty acid pools, thereby reducing the availability for eicasanoid-synthesizing enzymes and inflammation (21).
这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的, 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量, 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 摘要 我们建议在同情使用的基础上,为重度肠外营养相关胆汁淤积(结合胆红素6)患者提供omega-6主要脂质输注(Omegaven)。我们将在最长5个月的干预期间监测安全性参数。Omegaven将以1 gm/kg/天的剂量静脉输注,直至婴儿脱离肠外营养,持续时间不超过5个月。这是方案H-21344的延续。 I. 假设 由于本方案的同情使用性质,因此不适用。 二. 具体目标 为肠外营养(PN)相关胆汁淤积的危重婴儿提供一种机制,使其在没有令人满意的替代治疗的情况下接受Omegaven同情使用。 三. 背景和意义 肠外营养(PN)为因肠道长度或功能不足而无法吸收足够肠内营养的患者提供静脉营养补充。PN含有人类饮食中最基本形式的常量营养素构建模块(氨基酸和葡萄糖),通常与脂肪乳剂一起给药,以避免必需脂肪酸缺乏症,并提供非蛋白质热量的高热量来源。此外,PN含有必需的微量营养素(电解质、微量元素和维生素),可提供最佳营养方案。在20世纪60年代末PN发展之前,胃肠吸收功能不足的患者通常死于饥饿和随后的营养不良并发症(1,2)。今天,超过30,000名患者永久依赖肠外营养生存。然而,PN仍然与肝损伤相关,肝损伤的发生率不可预测,包括生化,即,血清转氨酶和碱性磷酸酶升高,以及组织学改变,如脂肪变性、脂肪性肝炎、肝硬化、胆汁淤积、纤维化和肝硬化(3,4)。这些异常可能随着PN给药持续时间的延长而加重,在儿科人群中更为常见。这种情况的其他风险因素包括早产、低出生体重、长期使用PN、缺乏伴随的肠内摄入、败血症和多次手术(5)。 虽然PN引起的肝损伤的病理学特征已被很好地描述,但这种并发症的病因、预防和治疗尚不清楚。存在多种假说来解释PN诱导的肝损伤的发病机制,包括肠道激素谱改变(6)、在没有肠内摄入的情况下细菌移位的倾向(7,8)、导致肝毒性胆汁酸清除率降低的肠道淤滞(8)以及PN溶液本身的直接缺陷或毒性成分导致葡萄糖热量摄取过多、脂质输注过多,或营养缺乏症,如必需脂肪酸缺乏症(9-11)。这些理论都没有得到一致的证实。目前认为PN相关肝毒性的病因是多因素的。这种疾病过程的可用治疗方案是有限的,最多取得了中等程度的成功。PN依赖患者的护理重点是逐渐增加肠内热量摄入,因为残余肠道适应允许PN中断(12)。事实上,实验和临床均表明,部分肠内营养在耐受时有助于防止PN相关肝损伤的发展(13-15)。在严重的难治性肝衰竭病例中,肝移植伴或不伴小肠移植仍然是唯一的治疗选择。 含omega-3脂肪酸脂肪乳剂的清除机制尚不清楚,但似乎在很大程度上不依赖于上述途径(17)。此外,omega-3脂肪酸溶液已被证明可减少新生脂肪生成(18),预防或减轻大鼠(19)和豚鼠中PN诱导的脂肪肝,并改善大鼠中高脂饮食诱导的脂肪肝的严重程度(20)。此外,ω-3脂肪酸可以干扰炎症的花生四烯酸途径(18,21)。它们可以取代组织脂肪酸池中的花生四烯酸,从而降低类花生酸合成酶和炎症的可用性(21)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEVEN A ABRAMS其他文献

STEVEN A ABRAMS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEVEN A ABRAMS', 18)}}的其他基金

EVALUATION OF THE USE OF DONOR HUMAN MILK FOR INFANTS WITH ABDOMINAL WALL DEFECT
腹壁缺陷婴儿使用供者母乳的评估
  • 批准号:
    8356736
  • 财政年份:
    2010
  • 资助金额:
    $ 2.59万
  • 项目类别:
EVALUATION OF CALCIUM, VITAMIN D, MAGNESIUM AND ZINC ABSORPTION IN HEALTHY
评估钙、维生素 D、镁和锌的健康吸收情况
  • 批准号:
    8356713
  • 财政年份:
    2010
  • 资助金额:
    $ 2.59万
  • 项目类别:
ZINC AND COPPER EXCRETION AND ABSORPTION IN INFANTS WITH OSTOMIES
造口婴儿的锌和铜排泄和吸收
  • 批准号:
    8356699
  • 财政年份:
    2010
  • 资助金额:
    $ 2.59万
  • 项目类别:
VITAMIN D STATUS AND IMPACT ON BONE MINERALIZATION IN HUMAN MILK FED HISPANIC
母乳喂养的西班牙裔人的维生素 D 状况及其对骨矿化的影响
  • 批准号:
    8356696
  • 财政年份:
    2010
  • 资助金额:
    $ 2.59万
  • 项目类别:
QUALITY IMPROVEMENT PROJECT - EVALUATION OF CURRENT STANDARD OF CARE
质量改进项目 - 评估当前护理标准
  • 批准号:
    8356752
  • 财政年份:
    2010
  • 资助金额:
    $ 2.59万
  • 项目类别:
ZINC AND COPPER EXCRETION AND ABSORPTION IN INFANTS WITH OSTOMIES
造口婴儿的锌和铜排泄和吸收
  • 批准号:
    8166718
  • 财政年份:
    2009
  • 资助金额:
    $ 2.59万
  • 项目类别:
EVALUATION OF THE USE OF DONOR HUMAN MILK FOR INFANTS WITH ABDOMINAL WALL DEFECT
腹壁缺陷婴儿使用供者母乳的评估
  • 批准号:
    8166750
  • 财政年份:
    2009
  • 资助金额:
    $ 2.59万
  • 项目类别:
Enhancing Dietary Iron and Zinc Bioavailability in Indian Children
提高印度儿童膳食铁和锌的生物利用度
  • 批准号:
    7665615
  • 财政年份:
    2009
  • 资助金额:
    $ 2.59万
  • 项目类别:
VITAMIN D STATUS AND IMPACT ON BONE MINERALIZATION IN HUMAN MILK FED HISPANIC
母乳喂养的西班牙裔人的维生素 D 状况及其对骨矿化的影响
  • 批准号:
    8166715
  • 财政年份:
    2009
  • 资助金额:
    $ 2.59万
  • 项目类别:
NUTRITIONAL MANAGEMENT OF INFANTS WITH BRONCHOPULMONARY DYSPLASIA (BPD): EFFE
支气管肺发育不良 (BPD) 婴儿的营养管理:EFFE
  • 批准号:
    8166685
  • 财政年份:
    2009
  • 资助金额:
    $ 2.59万
  • 项目类别:

相似海外基金

Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
  • 批准号:
    BB/Y006380/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.59万
  • 项目类别:
    Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
  • 批准号:
    24K17112
  • 财政年份:
    2024
  • 资助金额:
    $ 2.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
  • 批准号:
    2300890
  • 财政年份:
    2023
  • 资助金额:
    $ 2.59万
  • 项目类别:
    Continuing Grant
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
  • 批准号:
    23K06918
  • 财政年份:
    2023
  • 资助金额:
    $ 2.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
  • 批准号:
    23K05758
  • 财政年份:
    2023
  • 资助金额:
    $ 2.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
  • 批准号:
    23K04668
  • 财政年份:
    2023
  • 资助金额:
    $ 2.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
  • 批准号:
    2888395
  • 财政年份:
    2023
  • 资助金额:
    $ 2.59万
  • 项目类别:
    Studentship
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
  • 批准号:
    10761044
  • 财政年份:
    2023
  • 资助金额:
    $ 2.59万
  • 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
  • 批准号:
    10728925
  • 财政年份:
    2023
  • 资助金额:
    $ 2.59万
  • 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
  • 批准号:
    10757309
  • 财政年份:
    2023
  • 资助金额:
    $ 2.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了